Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world multicenter study of Shugan Jieyu capsule for hypertension with depression
ChiCTR2400094943Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Dec 2024
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Shugan Jieyu in hypertension (HTN) and major depressive disorder (MDD), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Overall effectiveness rate based on PHQ-9 at 12 weeks. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
Shugan Jieyu
03
Conditions
hypertension (HTN)major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2400094943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094943.